Request Demo

Last update 27 Mar 2025

Lecanemab

Last update 27 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-amyloid beta protofibril antibody, Immunoglobulin G1, anti-(human beta-amyloid protofibril) (human-mus musculus monoclonal BAN2401 heavy chain), disulfide with human-mus musculus monoclonal BAN2401 light chain, dimer, lecanemab-irmb

+ [7]

Target

APP

Action

inhibitors

Mechanism

APP inhibitors(Beta amyloid A4 protein inhibitors)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersOther Diseases

Active Indication

Dementia due to Alzheimer's disease (disorder)Mild cognitive disorderAlzheimer Disease+ [2]

Inactive Indication-

Originator Organization

Active Organization

+ [4]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (06 Jan 2023),

Alzheimer Disease

RegulationFast Track (United States), Accelerated Approval (United States), Priority Review (China), Innovative Licensing and Access Pathway (United Kingdom), Priority Review (Japan), Priority Review (United States), Breakthrough Therapy (United States)

Structure/Sequence

Sequence Code 315606586L

Source: *****

Sequence Code 315606587H

Source: *****

Clinical Trials associated with Lecanemab

NCT06871839

/ Not yet recruitingNot ApplicableIIT

The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease

Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families. Early intervention is regarded as an effective strategy to improve clinical symptoms, delay disease progression and maintain current quality of life. The humanized monoclonal antibody lencanemab (Lecanemab) was approved by the U.S. FDA in July 2023 for the treatment of mild cognitive impairment or mild dementia caused by AD, and was officially approved in January 2024 in China. Lencanemab highly targets soluble and insoluble neurotoxic β-amyloid (Aβ) proteins, reducing pathogenic Aβ plaque deposition and preventing its formation in the brains of AD patients, thus reducing neurotoxicity and improving patients' cognitive functions. In addition, lencanumab may also play a neuroprotective role by modulating synaptic plasticity and regulating neural network activity in brain neurons. However, there is a lack of clinical studies to prove this mechanism. In this study, we will enroll consecutive patients with early AD treated with lencanemab infusion as well as those receiving conventional anti-dementia therapy, and comprehensively assess the effects and intrinsic molecular mechanisms of lencanemab on synaptic function and neural networks using magnetic resonance imaging, molecular imaging positron emission tomography (PET), neuropsychological assessment, and analysis of blood cerebrospinal fluid samples.

Start Date10 Mar 2025

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

[+11]

NCT05999084

/ RecruitingNot ApplicableIIT

Georgia Memory Net Center for Medicare and Medicaid Services Registry for Anti-Amyloid Monoclonal Antibody Coverage with Evidence Development

The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.

Start Date06 Mar 2025

Sponsor / Collaborator

Emory University

[+1]

NCT06602258

/ RecruitingPhase 2

A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

Start Date30 Sep 2024

Sponsor / Collaborator

Eisai, Inc.

100 Clinical Results associated with Lecanemab

100 Translational Medicine associated with Lecanemab

100 Patents (Medical) associated with Lecanemab

406

Literatures (Medical) associated with Lecanemab

01 Apr 2025·JOURNAL OF AFFECTIVE DISORDERS

Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data

Article

Author: Zhu, Haohao ; Lu, Rongrong ; Gu, Jun ; Du, Zhiqiang ; Jiang, Ying ; Li, Zhaohui

OBJECTIVE:

This study aims to analyze the distribution of adverse events (AEs) related to Lecanemab in real-world settings based on FAERS database data.

METHODS:

Using the FAERS database, AE data related to Lecanemab was collected from Q3 2023 to Q2 2024. Signal mining was conducted using frequency and Bayesian methods to identify positive signals associated with Lecanemab.

RESULTS:

A total of 8,284,874 AE reports were collected, with 894 related to Lecanemab. Signal mining identified 22 SOCs, involving 46 PTs. Nervous system disorders had the highest report count, with Amyloid-Related Imaging Abnormalities (ARIA) being the most prominent AE, with high report numbers and signal strength, manifesting as brain edema, microhemorrhages, and iron deposits in the brain. Additionally, infusion-related reactions were common, including headache, chills, and fever. The study also revealed some new potential AEs, such as anger, cognitive disorder, disorientation, and abnormal dreams. Although these psychiatric symptoms had a lower report count, their high signal strength suggests that Lecanemab may impact patients' mental states. Rare but severe AEs, such as encephalitis, pancreatic carcinoma, and subdural hematoma, had low report numbers but high signal strength, highlighting potential risks for these severe events, especially in high-risk patients with relevant medical histories.

CONCLUSION:

This study unveils certain potential risks associated with Lecanemab in real-world applications. Further clinical studies are needed to validate these findings and provide guidance for safe medication practices.

01 Apr 2025·European Journal of Nuclear Medicine and Molecular Imaging

Lecanemab approval in EU: what should we be ready for?– the EANM perspective

Author: Yakushev, Igor ; Grimmer, Timo ; Tolboom, Nelleke ; Van Weehaeghe, Donatienne ; Traub-Weidinger, Tatjana ; Brendel, Matthias ; Cecchin, Diego ; Verger, Antoine ; Fernandez, Pablo Aguiar ; Guedj, Eric ; Fraioli, Francesco

04 Mar 2025·EXPERT OPINION ON BIOLOGICAL THERAPY

Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease

Review

Author: Altamura, Mario ; Leccisotti, Ivana ; Bellomo, Antonello ; Castellana, Fabio ; Sardone, Rodolfo ; Dibello, Vittorio ; Daniele, Antonio ; Lozupone, Madia ; Solfrizzi, Vincenzo ; Moretti, Maria Claudia ; Resta, Emanuela ; Zupo, Roberta ; Panza, Francesco

INTRODUCTION:

The amyloid cascade hypothesis postulated that the accumulation of amyloid-β (Aβ) was the first step of the Alzheimer's disease (AD) pathological process. Effective reduction of Aβ plaque load by numerous drug candidates, among which anti-Aβ monoclonal antibodies, has produced discussible clinical successes and several failures. It was questioned whether Aβ may be the principal AD pathogenic factor and a valid therapeutic target and if targeting Aβ different species could make the difference.

AREAS COVERED:

This review article summarized successes and failures of anti-Aβ monoclonal antibody therapy for AD, delineating the latest advances for their clinical development also according to their target engagement and downstream biomarkers.

EXPERT OPINION:

The preliminary success of the recent Phase III randomized clinical trials (RCTs) of lecanemab, donanemab, and remternetug, and lessons learned from the failure of previous anti-Aβ monoclonal antibodies RCTs, provided critical evidence to support the role of Aβ in AD pathogenesis. The loss of free Aβ instead of an Aβ toxicity may promote AD neuropathology. Cerebrospinal fluid analyses (i.e. increases in Aβ_1-42) may indicate a potential benefit of anti-Aβ monoclonal antibodies in AD and downstream biomarkers should be considered for providing comprehension in cognitive and clinical efficacy of future AD RCTs.

1,111

News (Medical) associated with Lecanemab

26 Mar 2025

·www.biospace.com

Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake

iStock, Liliia Bila Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago. Eisai has lowered its fiscal year 2027 sales projections for its Biogen -partnered Alzheimer’s disease therapy Leqembi, pointing to the drug’s “delayed uptake in the US market.” In a corporate presentation on Tuesday, Eisai’s sales simulations for Leqembi came out to ¥250 billion to ¥280 billion (approximately $1.7 billion to $1.9 billion) in sales for the fiscal year 2027, which ends in March 2028. This projection represents a roughly 50% drop from its previous forecast in March 2024, when the pharma set a fiscal 2027 goal of approximately ¥500 billion (around $3.3 billion) for the drug. “We consider FY2027 as a significant milestone,” Eisai wrote in its presentation deck, referring not only to its overall business but also to Leqembi, which it says, “has the potential to serve as a standard of care in Early AD [Alzheimer’s disease] treatment.” To boost Leqembi’s figures, Eisai is working on streamlining and optimizing the treatment pathway through targeted direct-to-patient engagement “to enhance brand awareness,” according to Tuesday’s presentation. Eisai hopes that building awareness of the drug could “support medical choice and decision-making.” Eisai is also fostering a “collaborative system” among integrated delivery networks and primary care physicians to reduce patient referral time. Aside from enhancing its treatment pipeline, Eisai is also working on different formulations of Leqembi. Earlier this year, the FDA accepted Eisai’s application for a subcutaneous formulation of the Alzheimer’s therapy for maintenance dosing, as opposed to IV infusion, and a verdict is expected by Aug. 31. The company will subcutaneous induction dosing thereafter, eyeing approval later this year or early in 2026. “The potential ability to administer [subcutaneous Leqembi with an autoinjector] for the entire treatment period may greatly improve the pathway that requires infusion capacity for traditional IV infusions,” according to Eisai’s Tuesday presentation. “For patients, this may contribute to significantly reducing the time and effort required for hospital visits.” Despite being the first-ever fully approved anti-amyloid antibody treatment for Alzheimer’s disease, Leqembi has had a rough time on the market . In November 2024, for instance, Eisai made another adjustment in its predictions and lowered its full fiscal year 2024 sales projections for Leqembi to around $280 million, down from its previous forecast of $370 million. There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales target. U.S. sales are also ticking upward, though overseas revenues still seem to be Leqembi’s main driver. There are around 13,500 patients on Leqembi, with 3,000 physicians prescribing the drug, Eisai revealed last month.

Drug ApprovalFinancial StatementAccelerated ApprovalBiosimilar

25 Mar 2025

·endpts.com

Eisai cuts Leqembi 2027 sales forecast by half but expects 'continued growth'

Eisai has slashed 2027 sales projections for its Biogen-partnered Alzheimer’s treatment Leqembi by roughly half. The Japanese drugmaker said it expects annual Leqembi sales to reach $1.7 billion to $1.9 billion in fiscal 2027 (250 to 280 billion yen) in presentation slides published on Tuesday. Last March, Eisai had projected $3.3 billion (500 billion yen) in 2027 sales. Eisai said the guidance reflects “delayed uptake in the US market,” according to the presentation slides. A company spokesperson cited multiple challenges in a statement to Endpoints News , including the length of time it takes for a patient to start treatment after their first visit with a physician. Biogen and Eisai have faced a series of challenges in Leqembi’s global rollout, including bottlenecks in US health systems. Eisai cut its fiscal 2024 sales expectations for Leqembi by about 25% in November. But during Eisai’s third-quarter earnings call last month, COO Keisuke Naito said the company is “moving towards a growth expansion phase of Leqembi.” Eisai said in its Q3 presentation last month that infusion capacity in the US has expanded, as has the use of PET scans to screen for amyloid plaque in the brain. The company estimated that roughly 13,500 patients were receiving Leqembi in the US by the end of January. Biogen and Eisai have also developed a subcutaneous autoinjector for Leqembi maintenance dosing, which executives have said could ease the burden on healthcare systems. That formulation is currently under review by the FDA, and a decision is expected in August. “We remain confident in Leqembi’s continued growth and the potential it holds for appropriate patients,” the Eisai spokesperson told Endpoints on Tuesday. A spokesperson for Biogen didn’t immediately respond to a request for comment.

Drug Approval

25 Mar 2025

·www.prnewswire.com

EISAI TO PRESENT LECANEMAB REAL-WORLD EXPERIENCE DATA AND FINDINGS FROM NEUROLOGY PORTFOLIO AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

NUTLEY, N.J., March 25, 2025 /PRNewswire/ -- Eisai Inc. announced today that the company will present the latest findings from its robust neurology portfolio, including data on real-world experience and continued maintenance dosing with our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI®) at the American Academy of Neurology (AAN) Annual Meeting, being held in San Diego, California, and virtually from April 5-9. Eisai will present two (2) oral presentations and seven (7) posters on lecanemab and the insomnia dual orexin receptor antagonist DAYVIGO® (lemborexant) CIV. Lecanemab Real World Experience Presentations On Wednesday, April 9, as part of Poster Session P12, "Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment" (11:45 AM - 12:45 PM PT), two posters will be presented on real-world experience with lecanemab, including results on efficacy and safety in the clinical setting and patient satisfaction with their treatment experience: Real-World Experience with Long-term Lecanemab Treatment: A Retrospective Chart Review in Early Alzheimer's Disease (Poster #012) Lecanemab in Clinical Practice: Real-World Treatment Outcomes from a Retrospective Neurological Clinic Case Series Review in Early Alzheimer's Disease (Poster #008) Oral Presentations Oral presentations include results on lecanemab maintenance dosing, which supports the need for continued treatment of this chronic, progressive disease. Additionally, a cost-effective analysis of lecanemab in Canada will be presented. "The data presented at AAN highlights not only the breadth and depth of real-world experience with lecanemab compared to clinical trials, but also the importance of ongoing treatment of this chronic progressive disease. Lecanemab clears highly toxic protofibrils that can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain," said Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. "We are eager to engage in scientific exchange that will continue to advance neurology research and deepen our understanding of lecanemab use in clinical practice, and we remain committed to improving the lives of people who are living with early Alzheimer's disease." Oral Presentations Session 23: Innovations in Dementia Treatment Poster Presentations Session P1: Aging, Dementia, and Behavioral Neurology: Alzheimer's Disease Diagnostics and Biomarkers Session P12: Aging, Dementia, and Behavior Neurology: Alzheimer's Treatment Session P9: Sleep 3 Industry Therapeutic Updates Sponsored by Eisai Inc. This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. * Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2 [Notes to editors] About lecanemab (LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S.,3 Japan,4 China,5 South Korea,6 Hong Kong,7 Israel,8 the United Arab Emirates,9 the United Kingdom,10 Mexico,11 Macau and Oman. Eisai has submitted applications for approval of lecanemab in 17 countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab's marketing authorization. LEQEMBI's approvals in these countries was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.12,13 The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. About Lemborexant (DAYVIGO®) Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible that orexin signaling which regulates wakefulness is not functioning normally, suggesting that inhibiting inappropriate orexin signaling may enable initiation and maintenance of sleep. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia. References Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi: 10.1038/s41467-021-23507-z. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Last accessed: March 2025. Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: March 2025. The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: March 2025. Pharmaceutical Technology. 2024. South Korea's MFDS approves Eisai-Biogen's LEQEMBI for Alzheimer's. Last accessed: March 2025. Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer's treatment. Last accessed: March 2025. BioSpace. 2024. Leqembi approved for the treatment of Alzheimer's disease in Israel. Last accessed: March 2025. United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: October 2024. BioSpace. 2024. Leqembi authorized for early Alzheimer's disease in Great Britain. Last accessed: March 2025. COFEPRIS authorizes innovative treatment for Alzheimer's patients. Available at: . Last accessed: March 2025. van Dyck, C., et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388:9-21. . Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: . SOURCE Eisai Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Drug ApprovalLicense out/in

100 Deals associated with Lecanemab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lecanemab	-	DB14580

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eisai Europe Ltd.	22 Aug 2024
Mild cognitive disorder	United Kingdom	Eisai Co., Ltd.	22 Aug 2024
Alzheimer Disease	United States	Eisai, Inc.	06 Jan 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 1	Japan	Eisai Co., Ltd.	01 Sep 2013
Brain Injuries, Traumatic	Preclinical	United States	BioArctic AB	15 Nov 2023
Down Syndrome	Preclinical	United States	BioArctic AB	15 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03887455 (Clarity AD, PRNewswire) Manual	Phase 3	Alzheimer Disease	1,795	lecanemab	ybdmapzjia(gmsrxmpehb) = pizbrspphb xxrhvuszwy (rkqrlkbkwn ) View more	Positive	30 Jul 2024
				Placebo	ybdmapzjia(gmsrxmpehb) = sesialwuse xxrhvuszwy (rkqrlkbkwn )
NCT03887455 (Clarity AD, Pubmed) Manual	Phase 3	Alzheimer Disease ApoE e4 carriers \| ApoE ε4 homozygous participants	3,407	Lecanemab 10 mg/kg biweekly	bnhzihaufs(plywiqikzt) = syglgkbwrw yqphpmavoz (nourdmqbks ) View more	Positive	10 May 2024
				placebo (Core Study)	gzwwjmdjrq(yqiuripwcg) = nuldsfjylz ndaacldqzu (ioifslazyj )
NCT03887455 (Clarity AD, AAN2024)	Phase 3	Alzheimer Disease amyloid PET centiloid levels	-	Lecanemab 10 mg/kg biweekly	ngxxqyjpac(tfforxvhxm) = ypgipbertw kvpegxqgir (zgsahcoava )	Positive	09 Apr 2024
				Placebo	ngxxqyjpac(tfforxvhxm) = lrjyehgbci kvpegxqgir (zgsahcoava )
NCT03887455 (Clarity AD, PRNewswire \| NEWS \| Corporate Publications) Manual	Phase 3	Alzheimer Disease	898	LEQEMBI (SC)	iwygtnvjdz(yzabboahpn) = bribqevmts fsspbynrhy (kclgtccnsk, 2.27) View more	Positive	25 Oct 2023
				LEQEMBI (IV)	iwygtnvjdz(yzabboahpn) = ipfjbcdzrc fsspbynrhy (kclgtccnsk, 1.14) View more
NCT03887455 (Clarity AD, FDA) Manual	Phase 3	Alzheimer Disease ApoE ε4	1,464	LEQEMBI 10 mg/kg	tadlozvqzc(sbywxbjwxf) = moygfymdqh chwcipdgyf (uargblccmx ) Met View more	Positive	06 Jan 2023
				Placebo	tadlozvqzc(sbywxbjwxf) = ktunoqotqu chwcipdgyf (uargblccmx ) Met View more
NCT01767311 (FDA) Manual	Phase 2	Alzheimer Disease ApoE ε4	315	LEQEMBI 10 mg/kg	mmnixtzdxm(okosbuyhla) = qkzmeaqexv ukxjbztnbo (yqslbrrnql, -3.91 to -0.72) View more	Positive	06 Jan 2023
				placebo	avhoorhgxe(jxlqhqkkyi) = fviexjplml nsjabtbrou (jugmjsvlwc ) View more
Study 201 Core (AAIC2022)	Not Applicable	APOE4 genotype	856	Lecanemab 10 mg/kg Q2W	ubfoevaonr(bmsrtefvus) = vsbjildvsa mwulkviclg (iidvtqdwal )	-	20 Dec 2022
NCT01767311 (BAN2401-G000-201, AAIC2022)	Phase 2	Alzheimer Disease	-	Lecanemab	hduvhdvckj(xqkzhpkpco) = fwwgrxopvp upzewnluko (kgwlqwjfih )	-	20 Dec 2022
NCT01767311 \| NCT02956486 \| NCT03887455 (AAIC2022)	Not Applicable	Alzheimer Disease PET \| CSF	-	Lecanemab	cbthjxlrcb(ynxzuqihqt) = xjlhpyonyt wdcvelkavu (zcwmezquqi ) View more	-	20 Dec 2022
				Elenbecestat	cbthjxlrcb(ynxzuqihqt) = rhnksjnyhq wdcvelkavu (zcwmezquqi ) View more
NCT01767311 (AAIC2022)	Phase 2	Alzheimer Disease	-	Lecanemab (BAN2401)	slkhrirtcc(vcadncgrrz) = oevtaciygh rxksbujzyq (ccjwywwsjc )	-	20 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis